Anuh Pharma Limited has informed the Exchange regarding 'appointment of Mr. P. N. Rao as General Manager - Quality.'.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 6.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anuh Pharma Limited held its Board meeting on 20th May 2026, approving several items including audited financial results for Q4 and FY 2025-26. The company reported revenue from operations of Rs. 77,165.74 lakhs (up 16.6% YoY from Rs. 66,151.49 lakhs), but profit after tax declined to Rs. 4,104.61 lakhs (vs Rs. 4,735.19 lakhs). EBITDA margin contracted to 8.56% from 10.64% in the prior year. The Board recommended a dividend of Rs. 1.50 per share (30% payout), subject to shareholder approval at the AGM on 12th August 2026. Key appointments include Mr. P. N. Rao as General Manager - Quality (effective 1st June 2026), and re-appointments of two Non-Executive Directors. Nine promoter group shareholders holding ~0.95% stake have sought re-classification from 'Promoter Group' to 'Public' category. The company also adopted new MOA and AOA and authorized KMPs to determine materiality of disclosures.
Revenue growth is positive but declining margins and PAT indicate cost pressures. The dividend recommendation provides shareholder returns. Promoter group re-classification requests (0.95% stake) may slightly reduce promoter holding if approved, though the impact on stock is likely minimal given small quantum.